Armata Pharmaceuticals (ARMP) Corporate presentation summary

Strategic highlights

• Phage-based anti-infectives offer alternatives to antibiotics, effective against resistant bacteria and protect the microbiome.

• Diversified pipeline targets critical infections, including S. aureus bacteremia and P. aeruginosa respiratory diseases.

• Three randomized controlled Phase 2 trials completed, showing positive topline results in key indications.

• Proprietary cGMP manufacturing platform enables high-purity, high-potency phage products and supports scalability.

• Strong leadership, deep industry partnerships, and non-dilutive government funding support ongoing development.

Clinical program progress

• AP-SA02 demonstrated statistically significant improvement over standard of care in complicated S. aureus bacteremia, with robust safety and efficacy data.

• FDA agreed Phase 2 results support advancing AP-SA02 to Phase 3, targeting a $2B+ market opportunity.

• AP-PA02 showed bacterial load reduction in chronic P. aeruginosa respiratory infections (CF and NCFB), with well-tolerated dosing.

• Clinical strategy includes parallel regulatory and commercial pathways, with potential for rapid approval and broad market impact.

• Additional pipeline programs address acute pneumonia and prosthetic joint infections.

Manufacturing and platform capabilities

• 10,000 sq ft in-house cGMP facility in Los Angeles supports late-stage trials and commercial production.

• Proprietary processes achieve industry-leading phage purity, enabling higher dosing and repetitive IV administration.

• Flexible, modular platform allows rapid adaptation to new indications and streamlined regulatory processes.

• Manufacturing innovations drive lower cost of goods and create opportunities for contract manufacturing revenue.

• In-house quality control and analytical labs reduce supply chain risks and support scalability.